Pembrolizumab versus Ipilimumab in Advanced Melanoma
Пембролизумаб по сравнению с ипилимумабом при распространённой меланоме
2015-04-19
SCID: 54.1/v63hv86k
Discuss with AI
Advanced melanomaIpilimumabPD-1 immune checkpointPembrolizumabProgression-free survival
Figures from the paper
Abstract (AI)
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Key Findings
1
Grade 3–5 treatment-related adverse events were less frequent with pembrolizumab (13.3% and 10.1%) than with ipilimumab (19.9%), with similar efficacy between pembrolizumab schedules.
2
In a randomized phase 3 trial of 834 patients, pembrolizumab significantly improved progression-free survival versus ipilimumab.
3
Objective response rates were substantially higher with pembrolizumab every 2 weeks (33.7%) and every 3 weeks (32.9%) than with ipilimumab (11.9%).
4
Six-month progression-free survival was 47.3% and 46.4% with pembrolizumab every 2 or 3 weeks, versus 26.5% with ipilimumab.
5
Twelve-month overall survival was higher with pembrolizumab every 2 weeks (74.1%) or every 3 weeks (68.4%) than with ipilimumab (58.2%).
Research Object
Patients with advanced melanoma treated with pembrolizumab or ipilimumab
Research Subject
Comparative efficacy and safety, including progression-free survival, overall survival, tumor response, and treatment-related toxicity of pembrolizumab versus ipilimumab
Publication Details
Publication Date
2015-04-19
Journal
Publisher
ISSN
Cited by
6068
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by6
Cancer treatment and survivorship statistics, 20222022
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma2016
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update2021
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up2017
Comprehensive review of targeted therapy for colorectal cancer2020
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions2022